SCHEMBL6479352

SCHEMBL6479352

COc1cc(Nc2ncnc(-n3c(Cl)nc4ccccc43)n2)cc(OC)c1OCCn1ccnn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.54
LCK P06239 7/20 0.54
MAPK14 Q16539 2/20 0.54
FGFR1 P11362 5/20 0.43
FLT1 P17948 5/20 0.43
FGFR2 P21802 4/20 0.43
FGFR4 P22455 4/20 0.43
FGFR3 P22607 4/20 0.43
FLT4 P35916 4/20 0.43
IGF1R P08069 2/20 0.41
SRC P12931 4/20 0.39
EPHB4 P54760 1/20 0.39
PDGFRB P09619 2/20 0.38
EGFR P00533 1/20 0.38
AURKB Q96GD4 2/20 0.38
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37
TEK Q02763 1/20 0.36
PTK2 Q05397 3/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478952 0.83 KDR (0.74) KDRLCKMAPK14FGFR1FLT1
SCHEMBL6493240 0.82 KDR (0.56) KDRLCKMAPK14FGFR1FLT1
SCHEMBL6488784 0.82 EPHB4 (0.45) KDRFGFR1FLT1FGFR2FGFR4
SCHEMBL6479597 0.78 KDR (0.57) KDRLCKMAPK14FGFR1FLT1
SCHEMBL6478557 0.77 PIK3CA (0.47) KDRLCKMAPK14PIK3CAMTOR
SCHEMBL6492567 0.74 LCK (0.60) KDRLCKMAPK14FGFR1FLT1
SCHEMBL6488628 0.73 LCK (0.58) KDRLCKMAPK14FGFR1FLT1
SCHEMBL14214730 0.69 KDR (0.82) KDRLCKMAPK14FGFR1FGFR2
SCHEMBL14214614 0.69 KDR (0.78) KDRLCKMAPK14FGFR1FLT1
SCHEMBL14214681 0.69 KDR (0.71) KDRLCKMAPK14IGF1RAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA KDR 4/4885LCK 1859/4885MAPK14 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.